Literature DB >> 17671682

Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro.

D J Scott1, A T Parkes, F Ponchel, M Cummings, I Poola, V Speirs.   

Abstract

Tamoxifen resistance (TAMr) in breast cancer is a serious clinical dilemma, with no satisfactory explanation. We hypothesised that changes in the expression of steroid hormone receptors (ERalpha, ERbeta), their downstream target genes (PR, pS2) and their associated co-regulators (AIB-1, SRC-1, SRA, NCoR-1, SMRT and REA) could be related to the acquisition of TAMr. To test this hypothesis, we developed in vitro TAMr cell line models by continuous exposure of MCF-7 cells to 4-hydroxytamoxifen (4-HT) over 12 (MCF-7MMU1) and 21 (MCF-7MMU2) months, respectively and examined the expression of the above by Western blotting and immunohistochemistry. In addition, we further examined the changes in global gene expression in TAMr cells in comparison with TAM-sensitive cells by microarray analysis. We report here that acquisition of TAMr is associated with changes in the expression of PR, pS2 and several co-activators, but not ERs. In addition, genes associated with cell cycle, cell adhesion and extracellular matrix, were up-regulated while those associated with apoptosis or growth factors/hormones were down-regulated. Based on our results, it appears that increased co-activator expression, in concert with alterations in genes associated with controlling cell proliferation and survival contribute to TAMr in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671682     DOI: 10.3892/ijo.31.3.557

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

1.  The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

Authors:  M D Bacolod; S M Lin; S P Johnson; N S Bullock; M Colvin; D D Bigner; H S Friedman
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

2.  High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer.

Authors:  Mehrdad Asghari Estiar; Rezvan Esmaeili; Ali-Akbar Zare; Leila Farahmand; Hassan Fazilaty; Ali Zekri; Narges Jafarbeik-Iravani; Keivan Majidzadeh-A
Journal:  Clin Exp Med       Date:  2016-12-01       Impact factor: 3.984

3.  Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence.

Authors:  Carolyn L Smith; Ilenia Migliaccio; Vaishali Chaubal; Meng-Fen Wu; Margaret C Pace; Ryan Hartmaier; Shiming Jiang; Dean P Edwards; M Carolina Gutiérrez; Susan G Hilsenbeck; Steffi Oesterreich
Journal:  Breast Cancer Res Treat       Date:  2012-09-27       Impact factor: 4.872

Review 4.  Estrogen receptor-beta and breast cancer: translating biology into clinical practice.

Authors:  Yuet-Kin Leung; Ming-Tsung Lee; Hung-Ming Lam; Pheruza Tarapore; Shuk-Mei Ho
Journal:  Steroids       Date:  2012-03-29       Impact factor: 2.668

5.  Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells.

Authors:  Joan S Lewis-Wambi; Heather E Cunliffe; Helen R Kim; Amanda L Willis; V Craig Jordan
Journal:  Eur J Cancer       Date:  2008-07-07       Impact factor: 9.162

6.  Nuclear receptor modulation--role of coregulators in selective estrogen receptor modulator (SERM) actions.

Authors:  Qin Feng; Bert W O'Malley
Journal:  Steroids       Date:  2014-06-16       Impact factor: 2.668

Review 7.  The function of steroid receptor coactivator-1 in normal tissues and cancer.

Authors:  Claire A Walsh; Li Qin; Jean Ching-Yi Tien; Leonie S Young; Jianming Xu
Journal:  Int J Biol Sci       Date:  2012-03-07       Impact factor: 6.580

8.  HEXIM1 is a critical determinant of the response to tamoxifen.

Authors:  W Ketchart; N Ogba; A Kresak; J M Albert; J J Pink; M M Montano
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

9.  Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice.

Authors:  E Buache; N Etique; F Alpy; I Stoll; M Muckensturm; B Reina-San-Martin; M P Chenard; C Tomasetto; M C Rio
Journal:  Oncogene       Date:  2011-02-28       Impact factor: 9.867

10.  Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.

Authors:  E J Campbell; E McDuff; O Tatarov; S Tovey; V Brunton; T G Cooke; J Edwards
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.